Re: FYI. $44K Grant to Dr. Zagon...?

[Guest guest]

" maxwell98king " <wjkeeman@...> wrote: " FYI. Below are websites for Dr.

Zagon... "

Thank you for posting Dr. Zagon's websites. But I am specifically

interested in the $44K grant. Does anyone have any details?

Maureen

(Gazorpa)

[Guest guest]

dr zagon is a researcher which means he does things with lab rats and

not people. and while his research is interesting jill smith who I

believe works with him does things with actual human beings.

I'm not trying to denigrate what he is doing -but you guys are not

lab rats and there are other things that affect you

jmho. he's a brilliant guy and the work is important but his

recommendations are from someone who works in a lab. as opposed to

jill who works with humans and her research has a very human side to

it because she not only looks at the science but does quality of life

studies along the way.

cyndi

On Aug 8, 2006, at 12:43 PM, maxwell98king wrote:

> FYI. Below are websites for Dr. Zagon. Most of his work seems to be

> with OGF (opioid growth factor) and cancer. But he was a pioneer in

> the understanding of LDN and immune related diseases.

> http://www.fred.psu.edu/ds/retrieve/fred/investigator/isz1

> http://www.fred.psu.edu/ds/retrieve/fred/investigator/isz1/completepub

>

>> Would you recommend LDN to a friend if they had a disease in which

> LDN could stop progression?

>> Response: The only legitimate study that I have (we are

> talking about statistics, etc) for low dose naltrexone is one that I

> know about - this is concerning Crohn's disease. And even this is a

> preliminary report. The internet is filled with claims about LDN -

> including some from doctors. Please be aware that science is not

> serving as underpinnings for these claims.

>

> Now, in saying this, please let me say that LDN has many

> potentially terrific effects. But all of this should be done under a

> physician's supervision. Take the LDN once a day - in our patent on

> this we recommended dosages of 3-10 mg of naltrexone/daily. I believe

> many now are using 4.5 mg/day - that is fine and was derived from our

> claims. Do not take this more than once a day. Do not take this if you

> are using opioid-based pain medications. Have a doctor examine the

> patient prior to beginning medication, making special assessment of

> the signs/symptoms that you want to treat. Have a follow-up visit in

> one month, and again in the 2nd month. Compare the outcomes to the

> original data. If nothing changes - or things decline - try a new

> medication.

>

>> I've viewed your many publications (not that I can really understand

> them) and noticed that most of your work now is in Opioid Growth

> Factor. Is that in any way related to how LDN works? Have you given up

> on naltrexone (LDN) as a disease treatment?

>> Response: Our discovery of LDN (we call it intermittent

> opioid receptor blockade) was made in a serendipity fashion, while

> looking for agents to alter growth (e.g., cancer, development). In

> actuality, LDN is really not doing anything to growth/biological

> activity. It is really interrupting the body with its natural

> chemicals - the enkephalins/endorphins. Therefore, our mission has to

> identify the precise opioid in the body that influences biological

> activities - this is methionine enkephalin - what is called opioid

> growth factor (OGF) to distinguish it from methionine enkephalin's

> role as a neurotransmitter in the nervous sytem. We then went on to

> identify the receptor for OGF - this is now called the OGF receptor

> (OGFr). We then went on to clone and sequence the gene for OGFr - it

> is one of the 20,000 genes in humans, and we know its chromosomal

> location. In fact, OGF is now being used in phase II clinical trials

> (we already passed phase I and have a publication in a journal on

> this) by our group to treat pancreatic cancer. How the OGF-OGFr axis

> does its thing - the mechanisms - as well as using this now to help

> patients, really is our focus.

>

> Let me add that we are still very interested in LDN. But

> using the real peptide involved - OGF - has a far more potent action

> than what we can get with the body's ability to be tricked into making

> more. But, let me tell you that we have make terrific progress in

> fields such as wound healing, because continuous blockade by

> naltrexone in cases of injury accelerates healing dramatically ( we

> have published many reports on this). So high dose naltrexone (HDN as

> you may want to call this) is an exciting adjunct to the LDN work.

>

> Hope you find this interesting,

>

>

>

>>

>> Does anyone have any further information about this $44,000 " pilot

>> grant " that the NMSS is supposedly giving Ian Zagon to study LDN?

>>

>> Is this grant for a clinical study? What are the parameters of the

>> grant? Does anyone know?

>>

>> Thanks...

>>

>> Maureen

>> (Gazorpa)

>>

>

>

>

>

>

>

>

>

>